Genprex, Inc. (GNPX)
| Market Cap | 135.45M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -18.48M |
| Shares Out | 47.37M |
| EPS (ttm) | -0.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 492,549 |
| Open | 2.69 |
| Previous Close | 2.72 |
| Day's Range | 2.64 - 2.85 |
| 52-Week Range | 2.24 - 7.72 |
| Beta | -0.96 |
| Analysts | Strong Buy |
| Price Target | 6.50 (+128.1%) |
| Est. Earnings Date | Nov 11, 2021 |
About GNPX
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in precli...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for Genprex stock is "Strong Buy" and the 12-month stock price forecast is 6.50.
News
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer an...
Genprex to Participate in Upcoming May Investor Conferences
AUSTIN, Texas--(BUSINESS WIRE)--Genprex will participate in conferences throughout May 2021.
Genprex in-licenses additional gene therapy technologies to treat non-small cell lung cancer
Genprex Inc (NASDAQ:GNPX) said that a major cancer research center in Houston has granted it an exclusive worldwide license for an additional portfolio of six patents and one patent application and rela...
Genprex wins centralized Institutional Review Board approval for its Acclaim-1 clinical trial in non-small cell lung ...
Genprex Inc (NASDAQ:GNPX) (FRA:2DE) has received centralized Institutional Review Board (IRB) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung can...
Genprex initiates site recruitment for Acclaim-2 clinical trial for its lung cancer drug REQORSA
Genprex Inc (NASDAQ:GNPX), a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, announced that it has started clinical trial site recruitment for its upcoming A...
Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Genprex commences clinical trial site recruitment for its combination clinical trial of REQORSA and Tagrisso in NSCLC
Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recogn...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex will receive the License of the Year award from University of Pittsburgh on April 22 for advances made on gene therapy program in diabetes.
Genprex presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research m...
Genprex Inc (NASDAQ:GNPX) said its collaborators have presented positive preclinical data for the combination of REQORSA, the company's proprietary TUSC2 immunogene therapy, in combination with chemothe...
Wall Street starts in the red
10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX) presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therape...
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer ...
AUSTIN, Texas--(BUSINESS WIRE)--Genprex collaborators report new, positive preclinical data for its lead drug candidate, REQORSA, at the 2021 AACR Annual Meeting.
Genprex targets non-small cell lung cancer and diabetes via gene therapy
Focused on developing life-changing therapies for patients with cancer and diabetes Advancing lead product REQORSA immunogene therapy for non-small cell lung cancer Struck licensing agreement with the ...
Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean
AUSTIN, Texas--(BUSINESS WIRE)--Genprex' EVP and Chief Operating Officer will present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean
Genprex to present preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting
Genprex Inc (NASDAQ:GNPX) said Tuesday that preclinical data for its lead drug candidate REQORSA, its proprietary TUSC2 immunogene therapy, in non-small cell lung cancer (NSLC), will be featured in two ...
Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two P...
AUSTIN, Texas--(BUSINESS WIRE)--Preclinical Data for Genprex' TUSC2 Immunogene Therapy Will Be Featured in Two Presentations at the 2021 AACR Annual Meeting
Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's President and CEO will present at the Virtual Oncology Investor Conference on March 29
Genprex to Participate in Upcoming March Investor Conferences
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at upcoming investor conferences in March 2021.
Genprex announces $25 million registered direct offering priced at-the-market
Genprex, Inc. (NASDAQ:GNPX) said it has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stoc...
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants
Genprex forms Clinical Advisory Board to support its oncology and diabetes development programs
Genprex Inc (NASDAQ:GNPX) announced Monday the formation of a Clinical Advisory Board (CAB) to support its oncology and diabetes development programs. Comprised of preeminent clinical specialists, the ...
Genprex Announces Formation of Clinical Advisory Board
AUSTIN, Texas--(BUSINESS WIRE)--Genprex forms a Clinical Advisory Board.
Genprex Recognizes World Cancer Day
AUSTIN, Texas--(BUSINESS WIRE)--Genprex honors World Cancer Day.
Genprex Issues Shareholder Letter and Provides Corporate Update
AUSTIN, Texas--(BUSINESS WIRE)--Genprex issues January 2021 shareholder letter.
Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present on February 4 at the Virtual Investor Conference.
The 17 Stocks That Outperformed Tesla In 2020
This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued...
Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual Expo
AUSTIN, Texas--(BUSINESS WIRE)--Genprex's CEO will present at the MoneyShow Virtual Conference on January 28.